E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017374 |
E.1.2 | Term | Friedreich's ataxia |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the long-term safety and tolerability of deferiprone in subjects with Friedreich’s ataxia (FRDA). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to evaluate the long-term efficacy of deferiprone for the treatment of FRDA.
The tertiary objectives are to evaluate the effect of deferiprone on: 1) cardiac function, 2) quality of life, and 3) functional status. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects who completed the ApoPharma study LA29-0207.
2. Female subjects of childbearing potential must have a negative pregnancy test. In addition, a female subject must confirm that during the study and for 30 days following the completion of the study or early termination she: • will use an effective method of contraception, OR • has had a tubal ligation (supporting evidence required), OR • has had a hysterectomy (supporting evidence required), OR • participates in a non-heterosexual lifestyle, OR • indicates her only male sexual partner has been sterilized (supporting evidence required). Effective methods of contraception include oral contraceptives, intrauterine devices (RIDs), diaphragm or condom, providing they are used with contraceptive foam or cream, or abstinence from sexual intercourse. Supporting evidence for sterilization consists of a surgical report or letter from the family physician.
3. Male subjects must confirm that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination. Effective methods of contraception for males include condoms or sterilization or abstinence from sexual intercourse or participation in a non-heterosexual lifestyle.
4. Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedules. |
|
E.4 | Principal exclusion criteria |
1. Serum Ferritin and Hemoglobin (Hb) levels are below the reference range for age and sex-matched controls.
2. Unable to complete T25FW AND with a score> 5 minutes in the 9HPT. (Subjects who can complete T25FW or with a score less than or equal to 5 minutes in the 9HPT will be allowed to enrol).
3. Doubling of score on 9HPT or T25FW compared to their study baseline results in LA29-0207.
4. History or evidence of neutropenia/agranulocytosis defined by a confirmed absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.
5. Occurrence of SAEs or any other AEs during the LA29-0207 study, which in the opinion of the investigator cause the patient’s participation in the extension study to be inappropriate.
6. Unable to comply with requirements of the protocol.
7. Pregnant, breastfeeding or planning to become pregnant during the study period.
8. QTc interval >450ms.
9. Have been on antioxidants prior to start of study treatment. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evaluation of long-term safety and tolerability of deferiprone in subjects with Friedreich's ataxia.
9-Hole Peg Test The 9HPT is a quantitative test of the functionality of the upper extremities. The test will be administered by a trained examiner (not necessarily the Investigator) in accordance with the Schedule of Events. The subject is instructed to place pegs into set holes as quickly as possible and then remove all the pegs. The test is performed two consecutive times with the dominant hand, followed by two consecutive times with the non-dominant hand. The maximum time allotted for each test (dominant or non-dominant hand) will be 5 minutes. The total time in seconds it takes the subject to complete the task is recorded. The average time for the four tests will be evaluated as a measure of treatment efficacy.
Timed 25-Foot Walk The T25FW is a quantitative mobility and leg function performance test. The test will be administered by a trained examiner (not necessarily the Investigator) in accordance with the Schedule of Events. The subject is instructed to walk 25 feet along a pre-defined straight course as quickly as possible. The task will be immediately repeated by having the subject walk back to the starting point. Subjects will be allowed to use assistive devices when completing this task. The total time in seconds it takes the subject to walk 25 feet will be recorded for each test. The average time for the two tests will be evaluated as a measure of treatment efficacy.
Low Contrast Letter Acuity LCLA is a quantitative Clinical measure to determine the level of visual dysfunction. Low-Contrast Sloan Letter Charts (LCSLC, Precision Vision, LaSalle, IL), which provide a quantitative and standardized method of visual function assessment, will be used for this study. These charts have gray letters of progressively smaller size on a white background. Two charts for low contrast (2.5% and 1.25%) as well as one chart for high contrast (100%; to determine visual acuity) will be used in this study. Subjects are requested to identify single letters on each chart at 3.2 meters distance for the 100% contrast and at 2 meters distance for the 2.5 and 1.25% contrast and scored based on number of letters correctly identified on each chart. The combined letter score from four charts will be recorded as a summary measure and will be evaluated as a measure of treatment efficacy. Subjects will be allowed to use their habitual distance correction glasses or contact lenses. The test will be administered by a trained individual.
International Cooperative Ataxia Rating Scale ICARS is a semi-quantitative scale based upon 19 test parameters that assess sensory and motor skills. ICARS allows measurement of postural and gait ataxia (seven tasks, 0-34 points), limb ataxia (six tasks on sides, and one writing task, 0-52 points), dysarthria of speech (two items, 0-8 points), and oculomotor signs (three items, 0-6 points). The overall score ranges from 0 to 100, with a score of 0 representing normal sensory and motor skills and 100 the worst. Subjects who are unable to perform a task receive the worst score, whatever the cause may be. ICARS testing will be performed by the same examiner (where possible) at various scheduled time points in the study as outlined in the Schedule of Events.
Friedreich’s Ataxia Rating Scale FARS is a neurological exam with 25 maneuvers and three quantitative performance measures, encompassing bulbar function, coordination of upper and lower limbs, peripheral nervous system function, deep tendon reflexes, stability and gait. FARS will be conducted by a trained examiner (not necessarily the Investigator) in accordance with the Schedule of Events. Whenever possible, FARS testing will be performed by the same examiner at each of the scheduled time points outlined in the Schedule of Events. Since there is some overlap between ICARS and FARS, the exams will be merged into one complete exam consisting of a total of 34 maneuvers.
Quality of Life The SF-b and SF-36 are questionnaires that assess a range of health concepts. The SF-b will be completed by the parent(s) or guardian(s) of subjects (aged 7 to <18 years), and the SF-36 will be completed by the adult subjects (aged 18 to 35 years), in accordance with the Schedule of Events.
Echocardiogram Echocardiogram (ECHO) to assess LVSF, LVEF and LV mass will be performed at visits outlined in the Schedule of Events.
Activities of Daily Living Activities of Daily Living (ADL) is a quantitative method to assess the functional status of the subject. Subjects are given a score between 0 and 36, with a score of o representing normal functional status, and 36 the worst. Whenever possible, the ADL will be performed by the same examiner at each of the scheduled time points outlined in the Schedule of Events. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |